WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material informat ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/iovance-biotherapeutics-inc-loss-submission-form/?id=150973&from=3 C ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Iovance To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Iovance between May 9, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 4, 2025 /PRNewswire/ -- Far ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Group 1 - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning potential securities fraud or unlawful business practices by the company and its officers [2][4] - Iovance reported a significant decline in quarterly total product revenue for Q1 2025, amounting to $49.3 million, down from $73.7 million in the previous quarter [4] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [4] Group 2 - Following the release of the financial results and guidance revision, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4] - Investors have until July 14, 2025, to request to be appointed as Lead Plaintiff in the class action if they purchased Iovance securities during the Class Period [2]

Core Viewpoint - A securities class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for allegedly making false or misleading statements regarding its business operations and the commercialization of its product, Amtagvi, leading to significant financial losses for investors [1][3]. Company Overview - Iovance is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumor cancers [2]. - The company's primary product, Amtagvi, is a tumor-derived autologous T-cell immunotherapy approved by the FDA on February 16, 2024, and launched commercially on February 20, 2024 [2]. Allegations in the Class Action - The lawsuit claims that during the class period, Iovance's management failed to disclose critical issues, including: - New Authorized Treatment Centers (ATCs) faced longer timelines to begin patient treatments with Amtagvi [3]. - Ineffectiveness of the sales team and ATCs in identifying and selecting patients, resulting in higher patient drop-off rates [3]. - These issues led to increased costs and reduced revenue as ATCs could not keep up with the manufactured product [3]. - Consequently, the positive statements made by the defendants regarding the company's business and prospects were materially misleading [3]. Financial Impact - On May 8, 2025, Iovance reported a significant decline in its 1Q25 total product revenue, which was $49.3 million, down from $73.7 million in the previous quarter [4]. - The company also revised its FY25 total product revenue guidance from a range of $450 million to $475 million down to $250 million to $300 million, citing recent launch dynamics of Amtagvi [4]. - Following this announcement, Iovance's share price dropped by $1.42, or 44.8%, closing at $1.75 per share on May 9, 2025, amid unusually high trading volume [4].

Group 1 - The DJS Law Group is reminding investors of a class action lawsuit against Iovance Biotherapeutics, Inc. for violations of federal securities laws [1] - Shareholders who purchased Iovance's securities between May 9, 2024, and May 8, 2025, are encouraged to contact the firm before July 14, 2025 [1] - The lawsuit alleges that Iovance made false and misleading statements regarding the timelines for treatment with Amtagvi and the effectiveness of its sales team and Authorized Treatment Centers [2] Group 2 - The complaint indicates that the failure to effectively select patients for Amtagvi led to patient drop-off, resulting in lower revenues and higher costs for the company [2] - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns [4]

Core Viewpoint - Iovance Biotherapeutics, Inc. announced the five-year follow-up results of the Phase 2 C-144-01 clinical trial for Amtagvi® (lifileucel), showing significant long-term benefits in patients with advanced melanoma, including durable responses and meaningful overall survival rates [2][4][6]. Group 1: Clinical Trial Results - The five-year analysis of the C-144-01 trial included 153 patients and demonstrated unprecedented durability in advanced melanoma patients previously treated with anti-PD-1 and targeted therapies [3][4]. - The objective response rate was 31.4%, with a median time to response of 1.4 months and a median duration of response of 36.5 months [4]. - Nearly one third of responders (31.3%) maintained ongoing responses at the five-year assessment, with a median overall survival (mOS) of 13.9 months and a five-year survival rate of 19.7% [4]. Group 2: Safety Profile - The safety profile of Amtagvi was consistent with nonmyeloablative lymphodepletion and interleukin-2 administration, with no new or late-onset adverse events reported at a median follow-up of 57.8 months [5][6]. - The incidence of adverse events decreased rapidly within the first two weeks after Amtagvi infusion [5]. Group 3: Regulatory Approval and Future Trials - In February 2024, the FDA granted accelerated approval to Amtagvi for treating adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody [6]. - Iovance is conducting the TILVANCE-301 Phase 3 trial in frontline advanced melanoma to confirm the clinical benefit of Amtagvi [6][7]. Group 4: Company Overview - Iovance Biotherapeutics aims to be a leader in developing tumor infiltrating lymphocyte therapies, with Amtagvi being the first FDA-approved T cell therapy for a solid tumor indication [16]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve patient outcomes [16].

Core Viewpoint - A lawsuit has been filed against Iovance Biotherapeutics, Inc. and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing treatments for melanoma and other solid tumor cancers [3]. - The company launched its key melanoma treatment, Amtagvi, in February 2024, administered at authorized treatment centers (ATCs) [3]. Allegations and Issues - The lawsuit alleges that Iovance misrepresented the effectiveness of its ATCs as a driver of demand for Amtagvi, while in reality, these centers faced long timelines for patient treatment and high patient drop-off rates due to ineffective patient identification and selection [4]. - Following disappointing financial results for Q1 2025, Iovance revised its full-year 2025 revenue guidance, attributing the poor performance to slow treatment timelines and high patient drop-off rates [5]. Stock Performance - On May 8, 2025, Iovance's stock price fell over 44%, dropping from $3.17 per share to $1.75 per share the following day, in response to the negative news regarding its financial results and operational challenges [6].